Skip to content
Study details
Enrolling now

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

Novo Nordisk A/S
NCT IDNCT07184632ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

220

Study length

about 1.2 years

Ages

18–65

Locations

2 sites in AZ, NE

About this study

This trial is testing how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of it is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 trial treatments in this trial, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take NNC0662-0419
  • 2.Take Placebo
PhasePhase 2
Primary goalPart A: Number of treatment-emergent adverse events (TEAE)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low7%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Part A: Number of treatment-emergent adverse events (TEAE), Part B: Relative change in body weight

Secondary: Part A: AUC; the area under the NNC0662-0419 plasma concentration-time curve, Part A: Change in body weight, Part A: Cmax; the maximum plasma concentration of NNC0662-0419, Part A: Relative change in body weight, Part B: Body weight reduction greater than or equal to (≥) 5% (Yes/No), Part B: Body weight reduction ≥ 10% (Yes/No), Part B: Body weight reduction ≥ 15% (Yes/No), Part B: Body weight reduction ≥ 20% (Yes/No)

Body systems

Endocrinology